The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer

The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer

Abstract CULLIN3‐based E3 ubiquitin ligase substrate‐binding adaptor gene SPOP is frequently mutated in prostate cancer (PCa). PCa harboring SPOP hotspot mutants (e.g., F133V) are resistant to BET inhibitors because of aberrant elevation of BET proteins. Here, we identified a previously unrecognized...

Full description

Bibliographic Details
Main Authors: Yuqian Yan, Jian Ma, Dejie Wang, Dong Lin, Xiaodong Pang, Shangqian Wang, Yu Zhao, Lei Shi, Hui Xue, Yunqian Pan, Jun Zhang, Claes Wahlestedt, Francis J Giles, Yu Chen, Martin E Gleave, Collin C Collins, Dingwei Ye, Yuzhuo Wang, Haojie Huang
Format: Article
Language:English
Published: Wiley 2019-11-01
Series:EMBO Molecular Medicine
Subjects:
BRD4
CBP/p300
NEO2734
prostate cancer
SPOP
Online Access:https://doi.org/10.15252/emmm.201910659

Internet

https://doi.org/10.15252/emmm.201910659

Similar Items